 | |
| Clinical data | |
|---|---|
| Other names | 2,3-DMPP; 2,3-XP; PAL-218; PAL218 |
| Drug class | Partialserotonin–norepinephrine releasing agent |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.012.540 |
| Chemical and physical data | |
| Formula | C12H18N2 |
| Molar mass | 190.290 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
2,3-Dimethylphenylpiperazine (2,3-DMPP; code namePAL-218) is amonoamine releasing agent anddesigner drug of thephenylpiperazine family.[1][2][3][4] It acts as apartialserotonin–norepinephrine releasing agent (SNRA), withEC50Tooltip half-maximal effective concentration (EmaxTooltip maximal efficacy) values of 24 to 26 nM (85%) forserotonin, 13.7 to 56 nM (62%) fornorepinephrine, and 1,207 to 1,320 nM (66%) fordopamine (22–96-fold lower than serotonin and norepinephrine).[1][2] Its possible activities atserotonin receptors were not reported.[1][2] The drug was first described in thescientific literature by 2009.[3][1][2]
 | Thispsychoactive drug-related article is astub. You can help Wikipedia byadding missing information. |